Interferon α2b mutant, fusion polypeptide comprising same, and use
By designing an affinity-weakened IFNα2b mutant fused with an anti-PD-1 antibody, the off-target toxicity and insufficient therapeutic window of IFNα2b drugs were resolved, achieving selective differentiation on PD-1 positive cells and higher tumor treatment efficacy.
WO2026138873A1 Publication Date: 2026-07-02INNOVENT BIOLOGICS (SUZHOU) CO LTD +1
0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2025/145113
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-11
- Filing Date
- 2025-12-24
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
Existing IFNα2b drugs exhibit off-target toxicity and non-specific inflammatory responses in tumor treatment, and the therapeutic window of the fusion protein TAK-573 of IFNα2b and anti-CD38 antibody needs to be improved.
Method used
By designing an affinity-weakened IFNα2b mutant and fusing it with an anti-PD-1 antibody, the binding to cell surface antigens is reduced by mutation or sequence substitution at specific sites, thereby reducing off-target toxicity and preserving activity against PD-1 positive cells.
Benefits of technology
It achieved selective differentiation between PD-1 positive and negative cells, reduced off-target toxicity, improved the therapeutic window, and demonstrated tumor-killing effects and higher tolerability in vivo.
✦ Generated by Eureka AI based on patent content.
Abstract
An interferon α2b mutant, and a fusion polypeptide and polypeptide construct comprising same. The fusion polypeptide or polypeptide construct comprising the interferon α2b mutant has weakened affinity to an interferon receptor, reduced off-target toxicity, and a tumor killing effect.
Need to check novelty before this filing date? Find Prior Art